Camostat

Camostat
Clinical data
Trade names	Foipan
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	B02AB04 (WHO) ;
Legal status
Legal status	US: Not FDA approved ; In general: ℞ (Prescription only);
Identifiers
	IUPAC name N,N-Dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate;
CAS Number	59721-28-7 ;
PubChem CID	2536;
IUPHAR/BPS	6432;
ChemSpider	2440 ;
UNII	0FD207WKDU;
ChEMBL	ChEMBL590799 ;
CompTox Dashboard (EPA)	DTXSID6044010 ;
Chemical and physical data
Formula	C20H22N4O5
Molar mass	398.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N;
	InChI InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) ; Key:XASIMHXSUQUHLV-UHFFFAOYSA-N ;
(verify)

Camostat (INN; development code FOY-305) is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. It is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.[1][2][3][4][5] It is approved for use in Japan.[6]

References

Okuno, M.; Kojima, S.; Akita, K.; Matsushima-Nishiwaki, R.; Adachi, S.; Sano, T.; Takano, Y.; Takai, K.; Obora, A.; Yasuda, I.; Shiratori, Y.; Okano, Y.; Shimada, J.; Suzuki, Y.; Muto, Y.; Moriwaki, Y. (2002). "Retinoids in liver fibrosis and cancer". Frontiers in Bioscience. 7 (4): d204–18. doi:10.2741/A775. PMID 11779708.
Hsieh, H. P.; Hsu, J. T. (2007). "Strategies of development of antiviral agents directed against influenza virus replication". Current Pharmaceutical Design. 13 (34): 3531–42. doi:10.2174/138161207782794248. PMID 18220789.
Kitamura, K.; Tomita, K. (2012). "Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension". Clinical and Experimental Nephrology. 16 (1): 44–8. doi:10.1007/s10157-011-0506-1. PMID 22038264.
Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion Jr, R.; Nunneley, J. W.; Barnard, D.; Pöhlmann, S.; McKerrow, J. H.; Renslo, A. R.; Simmons, G. (2015). "Protease inhibitors targeting coronavirus and filovirus entry". Antiviral Research. 116: 76–84. doi:10.1016/j.antiviral.2015.01.011. PMC 4774534. PMID 25666761.
Ueda, M.; Uchimura, K.; Narita, Y.; Miyasato, Y.; Mizumoto, T.; Morinaga, J.; Hayata, M.; Kakizoe, Y.; Adachi, M.; Miyoshi, T.; Shiraishi, N.; Kadowaki, D.; Sakai, Y.; Mukoyama, M.; Kitamura, K. (2015). "The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects". Nephron. 129 (3): 223–32. doi:10.1159/000375308. PMID 25766432.
"Camostat". drugs.com.

External links

Kunze H, Bohn E (May 1983). "Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes". Pharmacol Res Commun. 15 (5): 451–9. doi:10.1016/S0031-6989(83)80065-4. PMID 6412250.
Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W (1984). "Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion". Digestion. 30 (3): 171–8. doi:10.1159/000199102. PMID 6209186.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Okuno, M.; Kojima, S.; Akita, K.; Matsushima-Nishiwaki, R.; Adachi, S.; Sano, T.; Takano, Y.; Takai, K.; Obora, A.; Yasuda, I.; Shiratori, Y.; Okano, Y.; Shimada, J.; Suzuki, Y.; Muto, Y.; Moriwaki, Y. (2002). "Retinoids in liver fibrosis and cancer". Frontiers in Bioscience. 7 (4): d204–18. doi:10.2741/A775. PMID 11779708.

[2] Hsieh, H. P.; Hsu, J. T. (2007). "Strategies of development of antiviral agents directed against influenza virus replication". Current Pharmaceutical Design. 13 (34): 3531–42. doi:10.2174/138161207782794248. PMID 18220789.

[3] Kitamura, K.; Tomita, K. (2012). "Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension". Clinical and Experimental Nephrology. 16 (1): 44–8. doi:10.1007/s10157-011-0506-1. PMID 22038264.

[4] Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion Jr, R.; Nunneley, J. W.; Barnard, D.; Pöhlmann, S.; McKerrow, J. H.; Renslo, A. R.; Simmons, G. (2015). "Protease inhibitors targeting coronavirus and filovirus entry". Antiviral Research. 116: 76–84. doi:10.1016/j.antiviral.2015.01.011. PMC 4774534. PMID 25666761.

[5] Ueda, M.; Uchimura, K.; Narita, Y.; Miyasato, Y.; Mizumoto, T.; Morinaga, J.; Hayata, M.; Kakizoe, Y.; Adachi, M.; Miyoshi, T.; Shiraishi, N.; Kadowaki, D.; Sakai, Y.; Mukoyama, M.; Kitamura, K. (2015). "The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects". Nephron. 129 (3): 223–32. doi:10.1159/000375308. PMID 25766432.

[6] "Camostat". drugs.com.